SPONSOR
RemeGen Co., Ltd.
Total Trials
5
Recruiting
5
Phases
Phase 2, Phase 1, Phase 2, Phase 3
Conditions studied: Non-Small Cell Lung CancerBreast CancerHigh-risk Non-muscle Invasive Bladder CancerGastric Carcinoma
NCT06962865 Phase 2
Recruiting
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
Non-Small Cell Lung Cancer
NCT06178159 Phase 2
Recruiting
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Breast Cancer
NCT06378242 Phase 1, Phase 2
Recruiting
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
High-risk Non-muscle Invasive Bladder Cancer
NCT06389006 Phase 2
Recruiting
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
Breast Cancer
NCT07315750 Phase 3
Recruiting
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Gastric Carcinoma